-+ 0.00%
-+ 0.00%
-+ 0.00%

BioCryst Pharmaceuticals To Present Nine Abstracts From Hereditary Angioedema Portfolio At 2026 AAAAI Annual Meeting

Benzinga·02/11/2026 12:15:13
Listen to the news

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present nine abstracts from its hereditary angioedema (HAE) portfolio at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place in Philadelphia from February 27-March 2, 2026.

Data include six abstracts featuring new clinical trial and real-world outcomes with ORLADEYO® (berotralstat), the first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older, and three abstracts featuring new clinical trial outcomes with navenibart, a long-acting, monoclonal antibody plasma kallikrein inhibitor being investigated for prophylaxis to prevent attacks of HAE. These data include a late-breaking presentation highlighting positive interim results of the long-term, open-label ALPHA-SOLAR trial showing sustained, robust HAE attack suppression with navenibart administered every 3 or 6 months.